Heart:哪种药物治疗方式对保留射血分数的心力衰竭患者理想?

2017-08-09 MedSci MedSci原创

目前,心力衰竭和保留射血分数患者的临床药物试验尚未能证明对死亡率的改善作用。近期,一项发表在杂志Heart上的研究系统地搜索了从1996年1月至2016年5月Medline、Embase和Cochrane的对照试验中心登记册,入选评估了心力衰竭且左心室(LV)射血分数≥40%患者的药物治疗的随机对照试验(RCT)。此项研究的主要结局是全因死亡率。次要结局是心血管死亡率、心力衰竭导致的住院、运动能力

目前,心力衰竭和保留射血分数患者的临床药物试验尚未能证明对死亡率的改善作用。


近期,一项发表在杂志Heart上的研究系统地搜索了从1996年1月至2016年5月Medline、Embase和Cochrane的对照试验中心登记册,入选评估了心力衰竭且左心室(LV)射血分数≥40%患者的药物治疗的随机对照试验(RCT)。

此项研究的主要结局是全因死亡率。次要结局是心血管死亡率、心力衰竭导致的住院、运动能力(6分钟步行距离、运动时间、最大VO2)、生活质量和生物标志物(B型利尿钠肽、N-末端前B型利尿钠肽)。使用随机效应模型评估二元结果的合并相对风险(RR)以及连续结果的加权平均差异。

最终,此项研究共包括来自25个RCT的数据,包括了18101例患者的数据。与安慰剂相比,β-阻滞剂治疗的全因死亡率降低(RR:0.78,95%CI 0.65〜0.94,p = 0.008)。与安慰剂相比,ACE抑制剂、醛固酮受体阻滞剂、盐皮质激素受体拮抗剂和其他药物均无显著差异。在心血管死亡率中也观察到类似的结果。与安慰剂相比,没有单一药物能够减少因心力衰竭的住院治疗。

此项研究结果表明:对心脏衰竭和LV射血分数≥40%的治疗效果根据治疗类型而有所不同,β受体阻滞剂显示出了对全因死亡和心血管死亡率的降低作用。

原始出处:
Zheng SL, Chan FT, et al. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart. 2017 Aug 5. pii: heartjnl-2017-311652. doi: 10.1136/heartjnl-2017-311652. 

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1716174, encodeId=44ca1e1617458, content=<a href='/topic/show?id=7ec72e221c3' target=_blank style='color:#2F92EE;'>#保留射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27221, encryptionId=7ec72e221c3, topicName=保留射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ad32143633, createdName=Luyuxie_20, createdTime=Sun Mar 25 07:11:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975784, encodeId=73bb19e578455, content=<a href='/topic/show?id=fdbc6464eb2' target=_blank style='color:#2F92EE;'>#治疗方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64647, encryptionId=fdbc6464eb2, topicName=治疗方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 18 00:11:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356463, encodeId=0f8c135646398, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 11 09:11:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562658, encodeId=5d6415626582a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Aug 11 09:11:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232029, encodeId=4dcd2320290b, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Aug 10 06:34:45 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231986, encodeId=789c2319867f, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIu6CuPWSeEtKkcPK6pXia0Wt1dJvLaucV8iagH00Jfj5iaicv8FQ4Xvu2A0JBY3TUqlp2YeVjmUDPN2Q/132, createdBy=2da11615256, createdName=qingteng, createdTime=Wed Aug 09 23:26:22 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231908, encodeId=e0ad2319088a, content=学习学习,了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Aug 09 19:31:10 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231893, encodeId=5dfc231893f8, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Aug 09 18:53:29 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231889, encodeId=a1e623188989, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Aug 09 18:26:58 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231888, encodeId=383a231888a8, content=对心脏衰竭和LV射血分数≥40%的治疗效果根据治疗类型而有所不同,β受体阻滞剂显示出了对全因死亡和心血管死亡率的降低作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Wed Aug 09 18:26:08 CST 2017, time=2017-08-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1716174, encodeId=44ca1e1617458, content=<a href='/topic/show?id=7ec72e221c3' target=_blank style='color:#2F92EE;'>#保留射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27221, encryptionId=7ec72e221c3, topicName=保留射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ad32143633, createdName=Luyuxie_20, createdTime=Sun Mar 25 07:11:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975784, encodeId=73bb19e578455, content=<a href='/topic/show?id=fdbc6464eb2' target=_blank style='color:#2F92EE;'>#治疗方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64647, encryptionId=fdbc6464eb2, topicName=治疗方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 18 00:11:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356463, encodeId=0f8c135646398, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 11 09:11:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562658, encodeId=5d6415626582a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Aug 11 09:11:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232029, encodeId=4dcd2320290b, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Aug 10 06:34:45 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231986, encodeId=789c2319867f, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIu6CuPWSeEtKkcPK6pXia0Wt1dJvLaucV8iagH00Jfj5iaicv8FQ4Xvu2A0JBY3TUqlp2YeVjmUDPN2Q/132, createdBy=2da11615256, createdName=qingteng, createdTime=Wed Aug 09 23:26:22 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231908, encodeId=e0ad2319088a, content=学习学习,了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Aug 09 19:31:10 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231893, encodeId=5dfc231893f8, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Aug 09 18:53:29 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231889, encodeId=a1e623188989, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Aug 09 18:26:58 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231888, encodeId=383a231888a8, content=对心脏衰竭和LV射血分数≥40%的治疗效果根据治疗类型而有所不同,β受体阻滞剂显示出了对全因死亡和心血管死亡率的降低作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Wed Aug 09 18:26:08 CST 2017, time=2017-08-09, status=1, ipAttribution=)]
    2017-10-18 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1716174, encodeId=44ca1e1617458, content=<a href='/topic/show?id=7ec72e221c3' target=_blank style='color:#2F92EE;'>#保留射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27221, encryptionId=7ec72e221c3, topicName=保留射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ad32143633, createdName=Luyuxie_20, createdTime=Sun Mar 25 07:11:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975784, encodeId=73bb19e578455, content=<a href='/topic/show?id=fdbc6464eb2' target=_blank style='color:#2F92EE;'>#治疗方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64647, encryptionId=fdbc6464eb2, topicName=治疗方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 18 00:11:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356463, encodeId=0f8c135646398, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 11 09:11:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562658, encodeId=5d6415626582a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Aug 11 09:11:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232029, encodeId=4dcd2320290b, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Aug 10 06:34:45 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231986, encodeId=789c2319867f, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIu6CuPWSeEtKkcPK6pXia0Wt1dJvLaucV8iagH00Jfj5iaicv8FQ4Xvu2A0JBY3TUqlp2YeVjmUDPN2Q/132, createdBy=2da11615256, createdName=qingteng, createdTime=Wed Aug 09 23:26:22 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231908, encodeId=e0ad2319088a, content=学习学习,了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Aug 09 19:31:10 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231893, encodeId=5dfc231893f8, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Aug 09 18:53:29 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231889, encodeId=a1e623188989, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Aug 09 18:26:58 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231888, encodeId=383a231888a8, content=对心脏衰竭和LV射血分数≥40%的治疗效果根据治疗类型而有所不同,β受体阻滞剂显示出了对全因死亡和心血管死亡率的降低作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Wed Aug 09 18:26:08 CST 2017, time=2017-08-09, status=1, ipAttribution=)]
    2017-08-11 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1716174, encodeId=44ca1e1617458, content=<a href='/topic/show?id=7ec72e221c3' target=_blank style='color:#2F92EE;'>#保留射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27221, encryptionId=7ec72e221c3, topicName=保留射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ad32143633, createdName=Luyuxie_20, createdTime=Sun Mar 25 07:11:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975784, encodeId=73bb19e578455, content=<a href='/topic/show?id=fdbc6464eb2' target=_blank style='color:#2F92EE;'>#治疗方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64647, encryptionId=fdbc6464eb2, topicName=治疗方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 18 00:11:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356463, encodeId=0f8c135646398, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 11 09:11:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562658, encodeId=5d6415626582a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Aug 11 09:11:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232029, encodeId=4dcd2320290b, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Aug 10 06:34:45 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231986, encodeId=789c2319867f, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIu6CuPWSeEtKkcPK6pXia0Wt1dJvLaucV8iagH00Jfj5iaicv8FQ4Xvu2A0JBY3TUqlp2YeVjmUDPN2Q/132, createdBy=2da11615256, createdName=qingteng, createdTime=Wed Aug 09 23:26:22 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231908, encodeId=e0ad2319088a, content=学习学习,了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Aug 09 19:31:10 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231893, encodeId=5dfc231893f8, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Aug 09 18:53:29 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231889, encodeId=a1e623188989, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Aug 09 18:26:58 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231888, encodeId=383a231888a8, content=对心脏衰竭和LV射血分数≥40%的治疗效果根据治疗类型而有所不同,β受体阻滞剂显示出了对全因死亡和心血管死亡率的降低作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Wed Aug 09 18:26:08 CST 2017, time=2017-08-09, status=1, ipAttribution=)]
    2017-08-11 slcumt
  5. [GetPortalCommentsPageByObjectIdResponse(id=1716174, encodeId=44ca1e1617458, content=<a href='/topic/show?id=7ec72e221c3' target=_blank style='color:#2F92EE;'>#保留射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27221, encryptionId=7ec72e221c3, topicName=保留射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ad32143633, createdName=Luyuxie_20, createdTime=Sun Mar 25 07:11:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975784, encodeId=73bb19e578455, content=<a href='/topic/show?id=fdbc6464eb2' target=_blank style='color:#2F92EE;'>#治疗方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64647, encryptionId=fdbc6464eb2, topicName=治疗方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 18 00:11:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356463, encodeId=0f8c135646398, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 11 09:11:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562658, encodeId=5d6415626582a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Aug 11 09:11:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232029, encodeId=4dcd2320290b, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Aug 10 06:34:45 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231986, encodeId=789c2319867f, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIu6CuPWSeEtKkcPK6pXia0Wt1dJvLaucV8iagH00Jfj5iaicv8FQ4Xvu2A0JBY3TUqlp2YeVjmUDPN2Q/132, createdBy=2da11615256, createdName=qingteng, createdTime=Wed Aug 09 23:26:22 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231908, encodeId=e0ad2319088a, content=学习学习,了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Aug 09 19:31:10 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231893, encodeId=5dfc231893f8, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Aug 09 18:53:29 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231889, encodeId=a1e623188989, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Aug 09 18:26:58 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231888, encodeId=383a231888a8, content=对心脏衰竭和LV射血分数≥40%的治疗效果根据治疗类型而有所不同,β受体阻滞剂显示出了对全因死亡和心血管死亡率的降低作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Wed Aug 09 18:26:08 CST 2017, time=2017-08-09, status=1, ipAttribution=)]
    2017-08-10 龙胆草

    学习谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1716174, encodeId=44ca1e1617458, content=<a href='/topic/show?id=7ec72e221c3' target=_blank style='color:#2F92EE;'>#保留射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27221, encryptionId=7ec72e221c3, topicName=保留射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ad32143633, createdName=Luyuxie_20, createdTime=Sun Mar 25 07:11:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975784, encodeId=73bb19e578455, content=<a href='/topic/show?id=fdbc6464eb2' target=_blank style='color:#2F92EE;'>#治疗方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64647, encryptionId=fdbc6464eb2, topicName=治疗方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 18 00:11:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356463, encodeId=0f8c135646398, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 11 09:11:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562658, encodeId=5d6415626582a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Aug 11 09:11:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232029, encodeId=4dcd2320290b, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Aug 10 06:34:45 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231986, encodeId=789c2319867f, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIu6CuPWSeEtKkcPK6pXia0Wt1dJvLaucV8iagH00Jfj5iaicv8FQ4Xvu2A0JBY3TUqlp2YeVjmUDPN2Q/132, createdBy=2da11615256, createdName=qingteng, createdTime=Wed Aug 09 23:26:22 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231908, encodeId=e0ad2319088a, content=学习学习,了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Aug 09 19:31:10 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231893, encodeId=5dfc231893f8, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Aug 09 18:53:29 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231889, encodeId=a1e623188989, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Aug 09 18:26:58 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231888, encodeId=383a231888a8, content=对心脏衰竭和LV射血分数≥40%的治疗效果根据治疗类型而有所不同,β受体阻滞剂显示出了对全因死亡和心血管死亡率的降低作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Wed Aug 09 18:26:08 CST 2017, time=2017-08-09, status=1, ipAttribution=)]
    2017-08-09 qingteng

    学习了,谢谢

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1716174, encodeId=44ca1e1617458, content=<a href='/topic/show?id=7ec72e221c3' target=_blank style='color:#2F92EE;'>#保留射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27221, encryptionId=7ec72e221c3, topicName=保留射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ad32143633, createdName=Luyuxie_20, createdTime=Sun Mar 25 07:11:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975784, encodeId=73bb19e578455, content=<a href='/topic/show?id=fdbc6464eb2' target=_blank style='color:#2F92EE;'>#治疗方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64647, encryptionId=fdbc6464eb2, topicName=治疗方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 18 00:11:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356463, encodeId=0f8c135646398, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 11 09:11:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562658, encodeId=5d6415626582a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Aug 11 09:11:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232029, encodeId=4dcd2320290b, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Aug 10 06:34:45 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231986, encodeId=789c2319867f, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIu6CuPWSeEtKkcPK6pXia0Wt1dJvLaucV8iagH00Jfj5iaicv8FQ4Xvu2A0JBY3TUqlp2YeVjmUDPN2Q/132, createdBy=2da11615256, createdName=qingteng, createdTime=Wed Aug 09 23:26:22 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231908, encodeId=e0ad2319088a, content=学习学习,了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Aug 09 19:31:10 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231893, encodeId=5dfc231893f8, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Aug 09 18:53:29 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231889, encodeId=a1e623188989, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Aug 09 18:26:58 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231888, encodeId=383a231888a8, content=对心脏衰竭和LV射血分数≥40%的治疗效果根据治疗类型而有所不同,β受体阻滞剂显示出了对全因死亡和心血管死亡率的降低作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Wed Aug 09 18:26:08 CST 2017, time=2017-08-09, status=1, ipAttribution=)]
    2017-08-09 1dd8c52fm63(暂无匿称)

    学习学习,了解了解

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1716174, encodeId=44ca1e1617458, content=<a href='/topic/show?id=7ec72e221c3' target=_blank style='color:#2F92EE;'>#保留射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27221, encryptionId=7ec72e221c3, topicName=保留射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ad32143633, createdName=Luyuxie_20, createdTime=Sun Mar 25 07:11:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975784, encodeId=73bb19e578455, content=<a href='/topic/show?id=fdbc6464eb2' target=_blank style='color:#2F92EE;'>#治疗方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64647, encryptionId=fdbc6464eb2, topicName=治疗方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 18 00:11:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356463, encodeId=0f8c135646398, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 11 09:11:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562658, encodeId=5d6415626582a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Aug 11 09:11:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232029, encodeId=4dcd2320290b, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Aug 10 06:34:45 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231986, encodeId=789c2319867f, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIu6CuPWSeEtKkcPK6pXia0Wt1dJvLaucV8iagH00Jfj5iaicv8FQ4Xvu2A0JBY3TUqlp2YeVjmUDPN2Q/132, createdBy=2da11615256, createdName=qingteng, createdTime=Wed Aug 09 23:26:22 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231908, encodeId=e0ad2319088a, content=学习学习,了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Aug 09 19:31:10 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231893, encodeId=5dfc231893f8, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Aug 09 18:53:29 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231889, encodeId=a1e623188989, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Aug 09 18:26:58 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231888, encodeId=383a231888a8, content=对心脏衰竭和LV射血分数≥40%的治疗效果根据治疗类型而有所不同,β受体阻滞剂显示出了对全因死亡和心血管死亡率的降低作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Wed Aug 09 18:26:08 CST 2017, time=2017-08-09, status=1, ipAttribution=)]
    2017-08-09 flysky120

    学习一下知识了

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1716174, encodeId=44ca1e1617458, content=<a href='/topic/show?id=7ec72e221c3' target=_blank style='color:#2F92EE;'>#保留射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27221, encryptionId=7ec72e221c3, topicName=保留射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ad32143633, createdName=Luyuxie_20, createdTime=Sun Mar 25 07:11:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975784, encodeId=73bb19e578455, content=<a href='/topic/show?id=fdbc6464eb2' target=_blank style='color:#2F92EE;'>#治疗方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64647, encryptionId=fdbc6464eb2, topicName=治疗方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 18 00:11:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356463, encodeId=0f8c135646398, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 11 09:11:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562658, encodeId=5d6415626582a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Aug 11 09:11:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232029, encodeId=4dcd2320290b, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Aug 10 06:34:45 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231986, encodeId=789c2319867f, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIu6CuPWSeEtKkcPK6pXia0Wt1dJvLaucV8iagH00Jfj5iaicv8FQ4Xvu2A0JBY3TUqlp2YeVjmUDPN2Q/132, createdBy=2da11615256, createdName=qingteng, createdTime=Wed Aug 09 23:26:22 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231908, encodeId=e0ad2319088a, content=学习学习,了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Aug 09 19:31:10 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231893, encodeId=5dfc231893f8, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Aug 09 18:53:29 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231889, encodeId=a1e623188989, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Aug 09 18:26:58 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231888, encodeId=383a231888a8, content=对心脏衰竭和LV射血分数≥40%的治疗效果根据治疗类型而有所不同,β受体阻滞剂显示出了对全因死亡和心血管死亡率的降低作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Wed Aug 09 18:26:08 CST 2017, time=2017-08-09, status=1, ipAttribution=)]
    2017-08-09 wxl882001

    学习一下

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1716174, encodeId=44ca1e1617458, content=<a href='/topic/show?id=7ec72e221c3' target=_blank style='color:#2F92EE;'>#保留射血分数#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27221, encryptionId=7ec72e221c3, topicName=保留射血分数)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12ad32143633, createdName=Luyuxie_20, createdTime=Sun Mar 25 07:11:00 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1975784, encodeId=73bb19e578455, content=<a href='/topic/show?id=fdbc6464eb2' target=_blank style='color:#2F92EE;'>#治疗方式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64647, encryptionId=fdbc6464eb2, topicName=治疗方式)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 18 00:11:00 CST 2017, time=2017-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356463, encodeId=0f8c135646398, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 11 09:11:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562658, encodeId=5d6415626582a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Aug 11 09:11:00 CST 2017, time=2017-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232029, encodeId=4dcd2320290b, content=学习谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4Nd44v3xHnnictn9UpctwtH62EPQ59TMdI9lnqHMgQ16nH7GmGCfpzicsHgjibYVk6vwSpXrC86gMibRkoaIzf5HwSz7/0, createdBy=78cc1691107, createdName=龙胆草, createdTime=Thu Aug 10 06:34:45 CST 2017, time=2017-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231986, encodeId=789c2319867f, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIu6CuPWSeEtKkcPK6pXia0Wt1dJvLaucV8iagH00Jfj5iaicv8FQ4Xvu2A0JBY3TUqlp2YeVjmUDPN2Q/132, createdBy=2da11615256, createdName=qingteng, createdTime=Wed Aug 09 23:26:22 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231908, encodeId=e0ad2319088a, content=学习学习,了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Aug 09 19:31:10 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231893, encodeId=5dfc231893f8, content=学习一下知识了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160718/IMG578C993D395567540.jpg, createdBy=59b81918946, createdName=flysky120, createdTime=Wed Aug 09 18:53:29 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231889, encodeId=a1e623188989, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed Aug 09 18:26:58 CST 2017, time=2017-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=231888, encodeId=383a231888a8, content=对心脏衰竭和LV射血分数≥40%的治疗效果根据治疗类型而有所不同,β受体阻滞剂显示出了对全因死亡和心血管死亡率的降低作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/02/7354b3539aae6a0ccb1e0fff04c12084.jpg, createdBy=205b1984786, createdName=随梦飞扬, createdTime=Wed Aug 09 18:26:08 CST 2017, time=2017-08-09, status=1, ipAttribution=)]
    2017-08-09 随梦飞扬

    对心脏衰竭和LV射血分数≥40%的治疗效果根据治疗类型而有所不同,β受体阻滞剂显示出了对全因死亡和心血管死亡率的降低作用。

    0

相关资讯

Drug Safety:欧盟患者报告疑似药物不良反应的情况如何?

欧盟于2010年通过了新的药物警戒法规,并于2012年7月开始实施。立法规定,所有国家主管当局(NCA)和营销授权持有人(MAHs)都有义务记录和报告病人的疑似药物不良反应(ADR)。该描述性研究旨在通过EudraVigilance(EV)数据库,在新的药物警戒立法运行前3年和后3年对欧洲患者报告进行查询,并将患者报告与医疗保健专业人员(HCPs)报告进行比较。

Pharmacoepidemiol Drug Saf:妊娠期药物使用的安全性特征

2017年7月,发表在《Pharmacoepidemiol Drug Saf》的一项由挪威科学家进行的欧洲多国研究结果,揭示了妊娠期药物使用的安全性特征。

Iran J Med Sci:产后出血突发性感官听力损失研究报道

双边突发性感官听力损失(SSNHL)的流行度少于5%,并且大多数案例的病因并不为人们所知。由于肾脏和内耳许多结构和功能上的相似性,许多条件、疾病和药物对肾脏和耳蜗均具有影响和毒性。之前,有研究报道了患有CRF、尿毒症、经历血液透析治疗和ARF病人的SSNHL情况。最近,有研究人员报道了一个稀有的SSNHL情况,即产后严重出血诱发了肾衰竭和耳蜗损伤。病人年龄为22岁且为初次怀孕,妊娠月数足够,在产后

The Lancet:糖尿病药物艾塞那肽新发现

一项新的研究表明,糖尿病药物艾塞那肽exenatide的双重治疗效果,不仅可以用来降糖,而且对帕金森综合症也有着积极的效果。

ESMO Open:NSCLC免疫治疗:新治疗、新次序

免疫检点抑制剂已经或正在改变晚期NSCLC治疗模式。2017年7月29日发表在BMJ子刊ESMO Open文章盘点了checkpoint抑制剂在NSCLC关键研究数据,分析如何根据PD-L1表达选择免疫治疗的药物。

Drug Safety:评估上市前因素预测上市后包装警示和安全撤回

药物管理的一个重要目标是尽快了解新药的安全性问题。实现这一目标需要我们了解食品和药物管理局(FDA)药物审查中提供的信息是否可以预测产品批准后通常会发现的严重的安全问题。然而,关于这个话题的研究仍然不足。在本研究中,研究人员对上市前药物特征与严重的上市后安全行为关联性开展了调查。